Alnylam Pharmaceuticals (ALNY)
(Delayed Data from NSDQ)
$272.64 USD
-4.69 (-1.69%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $272.59 -0.05 (-0.02%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Alnylam Pharmaceuticals (ALNY) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$285.39 | $400.00 | $163.00 | 2.91% |
Price Target
Based on short-term price targets offered by 23 analysts, the average price target for Alnylam Pharmaceuticals comes to $285.39. The forecasts range from a low of $163.00 to a high of $400.00. The average price target represents an increase of 2.91% from the last closing price of $277.33.
Analyst Price Targets (23)
Broker Rating
Alnylam Pharmaceuticals currently has an average brokerage recommendation (ABR) of 1.70 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 27 brokerage firms. The current ABR compares to an ABR of 1.78 a month ago based on 27 recommendations.
Of the 27 recommendations deriving the current ABR, 16 are Strong Buy and three are Buy. Strong Buy and Buy respectively account for 59.26% and 11.11% of all recommendations. A month ago, Strong Buy made up 55.56%, while Buy represented 11.11%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/ALNY.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 16 | 16 | 15 | 14 | 13 |
Buy | 3 | 3 | 3 | 3 | 3 |
Hold | 8 | 8 | 9 | 9 | 9 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.70 | 1.70 | 1.78 | 1.81 | 1.84 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/16/2024 | Goldman Sachs | Salveen Richter | Hold | Strong Buy |
8/2/2024 | Not Identified | Not Identified | Hold | Hold |
8/2/2024 | Needham & Company | Joseph R Stringer | Moderate Buy | Moderate Buy |
8/2/2024 | Chardan Capital Markets | Keay T Nakae | Strong Buy | Strong Buy |
8/1/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/1/2024 | Piper Sandler | Edward A Tenthoff | Strong Buy | Strong Buy |
7/18/2024 | William Blair | Myles R Minter | Strong Buy | Strong Buy |
6/28/2024 | UBS | Eliana Merle | Not Available | Strong Buy |
6/25/2024 | Wells Fargo Securities | Tiago Fauth | Hold | Hold |
6/25/2024 | SVB Securities | Mani Foroohar | Hold | Hold |
6/25/2024 | Evercore Partners | Liisa A Bayko | Not Available | Strong Buy |
6/25/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
6/25/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
6/24/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
6/24/2024 | H.C. Wainwright & Co. | Patrick Trucchio | Strong Buy | Strong Buy |
6/24/2024 | Raymond James | Gary Nachman | Moderate Buy | Moderate Buy |
6/21/2024 | Canaccord Genuity | Whitney Ijem | Strong Buy | Strong Buy |
5/3/2024 | Cantor Fitzgerald & Co | Olivia Brayer | Hold | Hold |
4/8/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Ritu S Baral | Strong Buy | Strong Buy |
3/27/2024 | BMO Capital Markets | Kostas Biliouris | Strong Buy | Strong Buy |
2/16/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
2/15/2024 | Not Identified | Not Identified | Not Available | Hold |
12/1/2023 | Guggenheim Securities | Debjit Chattopadhyay | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.70 |
ABR (Last week) | 1.70 |
# of Recs in ABR | 27 |
Average Target Price | $285.39 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 81 of 253 |
Current Quarter EPS Est: | -0.49 |